Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
ACQUIRED COMPANY
 
My Lists

Modis Therapeutics  Acquired by Zogenix (2019 $ 250,000,000 )

409 13th Street, Suite 700
Oakland, CA 94612
USA
510-806-8562
Website Company Summary Management Team
Team

Management: Joshua A. Grass (CEO) Laurie S. Tsuruda (VP Pharmacology and Toxicology) Peter Barber (Chief Business Officer)Stacey Harte (VP Program Management)
Outside board: Ben Auspitz (F-Prime Capital) Rishi Gupta (OrbiMed Partner) Matthew R. Patterson (Audentes Therapeutics CEO)
Company

Business description: Modis Therapeutics, Inc. is a biopharmaceutical company focused on developing disease-modifying therapies for rare genetic diseases with high unmet medical need. It was formed in 2016 through a collaboration with academic experts in mitochondrial biology. The company's lead program (MT1621) is in clinical development for TK2d, an inherited mitochondrial disease. Modis Therapeutics is headquartered in Oakland, CA, with offices in New York City.
Capital

Rounds: 1
Recent fundings: Oct 2018
Capital raised: 30.0M
Last Round: 30.0M
Ownership: Acquired by Zogenix (2019 $ 250,000,000 )
VCs include: F-Prime Capital PartnersOrbiMed;  Aceras Life Sciences;  Osage University Partners

Last Tweets


 

Last Mentions


Overview
Record updated: Aug 2019
Sector: Medical
Year Founded: 2016
Rounds: 1
Recent fundings: Oct 2018
Capital raised: 30.0M
Last Round: 30.0M
Ownership: Acquired by Zogenix (2019 $ 250,000,000 )